Medicinal composition for treating non-small cell lung cancer and application thereof

A non-small cell lung cancer and composition technology, which is applied in the direction of drug combinations, active ingredients of heterocyclic compounds, active ingredients of heavy metal compounds, etc., can solve the problems of slow effect, inaccurate curative effect, and few cancer treatments

Inactive Publication Date: 2014-07-30
NORTHWEST A & F UNIV
View PDF3 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Traditional Chinese medicine can improve the immune function and anti-cancer ability of patients, and help patients pass the recovery period smoothly. However, simple

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating non-small cell lung cancer and application thereof
  • Medicinal composition for treating non-small cell lung cancer and application thereof
  • Medicinal composition for treating non-small cell lung cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: The effects of different combinations of targeted drugs and chemotherapeutic drugs on NSCLC cell lines were evaluated.

[0046] Cell Culture: The NSCLC cell line tested in the experiments was A549 cells obtained from ATCC. The cell culture medium used was RPMI medium 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 U / mL penicillin and 100 μg / mL streptomycin at 37 °C with a volume fraction of 5% CO 2 When cultured in an incubator, the cells grew adherently, and the cells in the logarithmic growth phase were used in the experiments.

[0047] Screening is done in two parts:

[0048] a. In the first set of experiments, the half inhibitory concentration (IC) of each drug was determined after being exposed to NSCLC cell lines for 72 hours 50 )value. Specific steps are as follows:

[0049] Collect logarithmic phase cells, inoculate in 96-well plate, add 100 μL to each well, adjust the concentration of cell suspension so that each well contains 200...

Embodiment 2

[0063] Example 2: The influence of Salvia miltiorrhiza on the anti-cancer effect of targeted drug and chemotherapeutic drug combination was evaluated.

[0064] Preparation of Salvia miltiorrhiza water extract: 80g of Salvia miltiorrhiza was decocted for 3 times, filtered through a vacuum filter, concentrated into about 40ml of medicinal solution, put into a vacuum drying oven to dry, and the yield was calculated as 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg / ml, and store it in a -20°C refrigerator for later use.

[0065] The steps and methods of the cell experiment were the same as those in Example 1, except that a drug-dosing group was added, in which the combined amount of targeting and chemotherapy drugs remained unchanged, but 10 mg / ml of Danshen water extract was added. The results...

Embodiment 3

[0066] Example 3: The effect of Astragalus membranaceus on the anti-cancer effect of targeted drug and chemotherapeutic drug combination was evaluated.

[0067] Preparation of astragalus water extract: 80g of astragalus was decocted for 3 times and the medicinal liquid was filtered through a vacuum filter, concentrated into about 40ml of medicinal liquid, put into a vacuum drying oven for drying, and the yield was calculated as 100% concentration. Take 1g of the water extract, add 10ml of ultrapure water, dissolve, centrifuge, take the supernatant, and then sterilize it through a 0.22μm microporous membrane to make a mother liquor with a concentration of 100mg / ml, and store it in a -20°C refrigerator for later use.

[0068] The steps and methods of the cell experiment were the same as those in Example 1, except that a drug-dosing group was added, in which the combined amount of targeting and chemotherapy drugs remained the same, but 10 mg / ml of astragalus water extract was adde...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition for treating non-small cell lung cancer. The medicinal composition comprises a target medicament, a chemotherapeutic medicament and a traditional Chinese medicament, wherein the target medicament is one or more of bortezomib, imatinib, gefitinib and sunitinib; the chemotherapeutic medicament is one or more of 5-fluorouracil, carboplatin, epirubicin, adriamycin and fludarabine; and the traditional Chinese medicament is one or more of salvia miltiorrhiza, astragalus membranaceus, sappanwood, Chinese pulsatilla root and portulaca oleracea. The medicinal composition has a remarkable synergetic treatment effect when being used for treating the non-small cell lung cancer, and can be used for remarkably strengthening the cancer-inhibition effect compared with treatment of a single medicament, so that the medicament dosage can be reduced, and the toxic and side effects of chemotherapeutic medicaments can be reduced.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a pharmaceutical composition for treating non-small cell lung cancer and its application in treating non-small cell lung cancer. Background technique [0002] Lung cancer is a disease that results from the uncontrolled growth of cells in the lung tissue. In the past 50 years, the incidence and mortality of lung cancer have increased year by year, and it has developed from a rare disease in the 20th century to the number one cancer killer in the world today. According to statistics, in industrialized countries and many cities in my country, the incidence of lung cancer ranks first among common tumors in men and second in common malignant tumors in women, and it has become the most common cause of death among malignant tumors. It is estimated that by 2025, the number of people dying of lung cancer alone in my country will be close to 1 million each year, becoming the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/71A61K36/537A61K36/481A61K36/48A61K36/185A61P35/00A61K31/506A61K31/282A61K31/513A61K31/52A61K31/704A61K31/7076
Inventor 王永华李鹏武子寅李丕栋汪纪楠周伟汝锦龙
Owner NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap